Article Versions Notes

Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao C, Sánchez-García J, Bernal T, et al. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study. Cancers. 2022; 14(23):5799. https://doi.org/10.3390/cancers14235799

Ayala, Rosa, Gonzalo Carreño-Tarragona, Eva Barragán, Blanca Boluda, María J. Larráyoz, María Carmen Chillón, Estrella Carrillo-Cruz, Cristina Bilbao, Joaquín Sánchez-García, Teresa Bernal, and et al. 2022. "Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study" Cancers 14, no. 23: 5799. https://doi.org/10.3390/cancers14235799

Ayala, R., Carreño-Tarragona, G., Barragán, E., Boluda, B., Larráyoz, M. J., Chillón, M. C., Carrillo-Cruz, E., Bilbao, C., Sánchez-García, J., Bernal, T., Martinez-Cuadron, D., Gil, C., Serrano, J., Rodriguez-Medina, C., Bergua, J., Pérez-Simón, J. A., Calbacho, M., Alonso-Domínguez, J. M., Labrador, J., ... Montesinos, P. (2022). Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study. Cancers, 14(23), 5799. https://doi.org/10.3390/cancers14235799